PD-1/PD-L1-IN-61 

PD-1/PD-L1-IN-61 is a PD-1/PD-L1 interaction inhibitor with a human IC₅₀ of 5.3 nM. PD-1/PD-L1-IN-61 embeds into the hydrophobic pocket at the PD-L1 dimer interface, stabilizing binding through hydrogen bonds and π-π stacking with PD-L1 residues. PD-1/PD-L1-IN-61 acts as an immune activator, enhances immune-killing activity of peripheral blood mononuclear cells against cancer cells, restores T-cell immune function, and promotes IFN-γ secretion. PD-1/PD-L1-IN-61 can be used for the research of triple-negative breast cancer^[1].

PD-1/PD-L1-IN-61 (III-4) (1-16 μM) shows negligible cytotoxicity against MDA-MB-231 and Jurkat cells^[1].
PD-1/PD-L1-IN-61 (0.5-2 μM) dose-dependently enhances PBMC-mediated killing of MDA-MB-231 cells, inducing 38.4% tumor cell killing at 1 μM^[1].
PD-1/PD-L1-IN-61 (10-1000 nM) dose-dependently promotes IFN-γ secretion from hPBMCs, with significant increases at 100 nM and 1000 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

776.83

C₄₂H₄₄N₆O₉

2983098-90-2

OC(CC1)CCN1CC(O2)=NN=C2C3=C(C)C(C4=CC=CC(COC5=C([N+]([O-])=O)C=C(CN[C@@H](C(C)O)C(O)=O)C(OCC6=CC(C#N)=CC=C6)=C5)=C4C)=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xie L, et al. Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint[J]. ACS Medicinal Chemistry Letters, 2026.